Skip to main content
Scilex Holding Co logo

Scilex Holding Co — Investor Relations & Filings

Ticker · SCLX ISIN · US80880W2052 LEI · 529900SPEA2C7YTTYP45 US Manufacturing
Open in API
Filings indexed 686 across all filing types
Latest filing 2023-02-15 Regulatory Filings
Country US United States of America
Listing US SCLX

About Scilex Holding Co

https://www.scilexholding.com/

Scilex Holding Co. is a company focused on the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. The company's portfolio targets indications with high unmet medical needs and features therapies with proprietary drug delivery systems. These systems include an advanced topical patch technology for optimized drug delivery through the skin, an anti-inflammatory oral solution designed for individualized dosing in high-risk patients, and a liquid ready-to-use analgesic for migraine relief. Scilex aims to provide effective alternatives to opioid medications to improve patient quality of life.

Recent filings

Filing Released Lang Actions
424B3
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed pursuant to the Securities Exchange Act of 1934, dated February 13, 2023. It reports a significant corporate event: the acquisition of rights related to a pharmaceutical product (ELYXYB) from other companies. The document includes details about the acquisition agreement, licenses, and obligations assumed, but does not contain comprehensive financial statements or detailed financial performance data. It is not an annual or quarterly report, nor is it an earnings release or investor presentation. The filing is a regulatory announcement of a material event, which fits the category of Regulatory Filings (RNS). The document length (7324 characters) and content confirm it is a standalone report of a corporate event rather than a report publication announcement or a full financial report.
2023-02-15 English
424B3
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, as indicated by the header and the text. It reports a specific event: the acquisition of rights related to a product (ELYXYB) and the assumption of obligations under an asset purchase agreement. The document includes details about the transaction, the parties involved, and the licenses acquired. It does not contain comprehensive financial statements or detailed financial performance data typical of Annual Reports (10-K) or Interim Reports (IR). It is not a prospectus or a proxy statement, nor is it a transcript or an earnings release. The document is a regulatory filing reporting a material event, which fits the category of Regulatory Filings (RNS). The length of the document (over 10,000 characters) and the detailed event description confirm it is not merely an announcement or a short notice. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-02-15 English
424B3
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed pursuant to the Securities Exchange Act of 1934. It includes an acquisition announcement of rights related to a product, details about the transaction, and signatures. It is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a proxy, earnings release, or other specific report type. The document is a regulatory filing reporting a material event (acquisition) and related information. Therefore, it fits best under Regulatory Filings (RNS). The document length (7315 characters) and content confirm it is not a brief announcement or a report publication announcement but a substantive regulatory filing.
2023-02-15 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text describes an acquisition of rights related to a product, including licenses and obligations assumed, but does not contain detailed financial statements or comprehensive financial analysis. The document is relatively short (4307 characters) and focuses on reporting a specific event rather than providing a full financial report or earnings release. It is not an Annual Report, Interim Report, Earnings Release, or any other detailed financial report. It is also not a proxy statement, voting results, or management change announcement. The Form 8-K is a regulatory filing used to disclose material events, so the appropriate classification is Regulatory Filings (RNS).
2023-02-13 English
VCKA 13GA
Major Shareholding Notification
2023-02-13 English
424B3
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 9, 2023, reporting the entry into an Amended and Restated Standby Equity Purchase Agreement. The content details the terms of a financing agreement allowing the company to sell up to $500 million of common stock to an investor. It includes legal and financial terms of the agreement, conditions, and references to prior filings. This is a clear update on the company's capital raising activities and financing arrangements, not a full financial report or earnings release. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and detail confirm it is not a mere announcement but a substantive filing about financing.
2023-02-09 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.